Timing of Treatment for Advanced Kidney Cancer
For patients with advanced renal cell carcinoma, no difference in survival was observed between those who underwent treatment immediately after diagnosis and those who postponed it by 3 months or more. These research findings were published by Eduardo L. Morgenfeld, MD, of Instituto Oncológico Henry Moore, Buenos Aires, Argentina, and colleagues, in the Journal of Clinical Oncology.
“Most of the treatment guidelines for advanced renal cancer agree about what drugs must be used but don’t indicate when the treatment should be started,” the investigators reported. “This decision is left to the desire of the patient and/or the common sense of the doctor.”
Between January 2001 and November 2016, 828 patients diagnosed with renal cell carcinoma were followed at their institution. They selected all patients with clear cell or papillary stage IV renal cell carcinoma who received systemic treatment (n=80) and separated them into 2 groups based on the time of treatment initiation: 47 patients in group A (immediate = within 3 months of diagnosis) and 33 patients in group B (delayed = beyond 3 months of diagnosis). The groups were similar in age, surgical treatment, metastatic sites, and systemic treatments.
There was no difference in survival rates with immediate or delayed treatments. The median survival for group A was 20.9 months and for group B was 29.8 months (P=.9).